PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.28%
Both yoy net incomes decline, with TRAW at -29.04%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
1.30%
D&A growth of 1.30% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
41.15%
SBC growth while TRAW is negative at -6.45%. John Neff would see competitor possibly controlling share issuance more tightly.
170.16%
Well above TRAW's 165.33% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
170.16%
Some yoy usage while TRAW is negative at -142.31%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
169.42%
Some yoy increase while TRAW is negative at -1384.38%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-4.39%
Negative yoy CFO while TRAW is 19.31%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
94.15%
CapEx growth of 94.15% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-97.06%
Negative yoy issuance while TRAW is 659.34%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.